Roflumilast: A green signal is yet to come

Journal of Thoracic Disease

Volumn 5, Issue 3, 2013, Pages 213-215

  Lone, Nazir ^a   Oba, Yuji ^a  

^a UNIVERSITY OF MISSOURI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; PHOSPHODIESTERASE; PLACEBO; ROFLUMILAST;

AGING; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE PREDISPOSITION; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; EDITORIAL; ENZYME INHIBITION; GASTROINTESTINAL DISEASE; HEART ATRIUM FIBRILLATION; HIGH RISK PATIENT; HUMAN; IMMOBILIZATION; IMMUNOMODULATION; LUNG FUNCTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MENTAL DISEASE; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; OXYGEN THERAPY; PATHOGENESIS; POSTMARKETING SURVEILLANCE; PREVALENCE; RISK BENEFIT ANALYSIS; RISK FACTOR; SMOKING; SMOKING CESSATION; SUICIDAL BEHAVIOR;

EID: 84881495232     PISSN: 20721439     EISSN: 20776624     Source Type: Journal    
DOI: 10.3978/j.issn.2072-1439.2013.05.11     Document Type: Editorial

References (20)

1. The world health report 2008-primary health care (now more than ever). Geneva: World Health Organization. Available online: http://www.who. int/whr/2008/en/index.html
2. Jemal A, Ward E, Hao Y, et al. Trends in the leading causes of death in the United States, 1970- 2002. JAMA 2005;294:1255-9.
3. Anthonisen NR, Connett JE, Enright PL, et al. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 2002;166:333-9.
4. Feary JR, Rodriques LC, Smith CJ, et al. Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care. Thorax 2010;65:956-62.
5. Hawkins NM, Huang Z, Pieper KS, et al. Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Eur J Heart Fail 2009;11:292-8.
6. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? the potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003;107:1514-9.
7. Suissa S, Hemmelgarn B, Blais L, et al. Bronchodilators and acute cardiac death. Am J Respir Crit Care Med 1996;154:1598-602.
8. Maxwell SR, Moots RJ, Kendall MJ. Corticosteroids: do they damage the cardiovascular system?. Postgrad Med J 1994;70:863-70.
9. Sholter DE, Armstrong PW. Adverse effects of corticosteroids on the cardiovascular system. Can J Cardiol 2000;16:505-11.
10. Rabe KF. Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. Br J Pharmacol 2011;163:53-67.
11. Pinner NA, Hamilton LA, Hughes A. Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease. Clin Ther 2012;34:56-66.
12. White WB, Cooke GE, Kowey PR, et al. Cardiovascular Safety In Patients Receiving Roflumilast for the Treatment of Chronic Obstructive Pulmonary Disease. Chest 2013. [Epub ahead of print].
13. Ferreira-González I, Busse JW, Heels-Ansdell D, et al. Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials. BMJ 2007;334:786.
14. Oba Y, Lone NA. Efficacy and safety of roflumilast in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Ther Adv Respir Dis 2013;7:13-24.
15. Mannino DM, Kiriz VA. Changing the burden of COPD mortality. Int J Chron Obstruct Pulmon Dis 2006;1:219-33.
16. Puhan M. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease Cochrane Database Syst Rev 2011;(8):ED000028.
17. US Department of Health and Human Services. Food and Drug Administration, Pulmonary-Allergy Drugs Advisory Committee (PADAC). Available online: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/UCM212109.pdf
18. Giembycz MA. An update and appraisal of the cilomilast phase III clinical development programme for chronic obstructive pulmonary disease. Br J Clin Pharmacol 2006;62:138-52.
19. Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013;187:347-65.
20. Roflumilast: doubtful efficacy but clear harms in COPD. Prescrire Int 2013;22:5-9.